{"source_content":"敬请阅读末页的重要说明证券研究报告|行业定期报告日用消费|医药生物推荐（维持）批签发向国产龙头集中，强者恒强2019年07月30日血制品行业2019上半年批签发报告上证指数2952行业规模占比%股票家数（只）2807.7总市值（亿元）365856.8流通市值（亿元）277076.3行业指数%1m6m12m绝对表现-0.823.8-9.4相对表现-1.53.1-18.8资料来源：贝格数据、招商证券相关报告1、《每周药事2019年第28周—8月中报季，业绩表观增速最重要》2019-07-282、《每周药事2019年第28周—科创板交易首周，关注医疗器械板块》2019-07-213、《每周药事2019年第28周—第一批带量采购新政的博弈分析》2019-07-14本篇报告回顾了2019年上半年血制品各类产品批签发概况，印证我们在20190324报告所提出观点：血制品行业受新兴事件影响明显，批签发的不足有利于渠道库存的出清和产品出厂价的提升，导致行业景气度的提升。上半年白蛋白国产企业份额提升明显。我们认为血制品行业经过短期的调整，未来行业仍将向龙头企业集中，继续强烈推荐血制品龙头天坛生物、华兰生物，建议关注博雅生物等。2019H1白蛋白国产批签发占比提升，进口批签发边际改善。2019H1白蛋白批签发1986.6万瓶，同比-7%，新兴事件导致白蛋白供不应求，完全符合我们在20190324报告《血制品批签发趋紧，行业迎来阶段性机会》的观点。批签发下降也使白蛋白从2月份开始出现供不应求，国产龙头企业如天坛生物等受益明显。当然，19Q2批签发同比仅下降3%，降幅较19Q1的-12%明显收窄，进口白蛋白从Q2开始，逐渐恢复批签发。预计下半年白蛋白批签发仍将继续改善。整体来看，白蛋白的企业库存和渠道库存都出清，即使下半年供应逐渐恢复，我们估计今年到明年，白蛋白价格也将维持稳定。静丙批签发同比略降，龙头企业的企业库存和渠道库存已经下降。静丙19H1批签发465.0万瓶，同比-7%，19Q2同比-20%。我们判断原因是，一方面，新兴事件导致静丙的批签发速度有所放慢，另一方面，静丙去年年底企业库存仍然较多，企业在年初计划可能会增加特免生产，控制静丙生产。但是，由于新兴事件导致医生患者不信任小企业，静丙需求向大企业集中，因此，龙头企业的静丙的企业库存和渠道库存在上半年都出现下降，景气向好。因子类的企业份额出现变化。VIII因子19H1批签发67.9万瓶，同比-19%，19Q2同比-42%。PCC19H1批签发41.0万瓶，同比-24%，19Q2同比-23%，八因子和PCC批签发的同比下降，都是由于主要供应商华兰生物生产线改造导致批签发延后，我们预计下半年华兰生物这两个因子类产品的批签发将大幅增长。纤原19H1批签发数量43.4万瓶，同比+29%，山东泰邦的批签发量上升较快。风险提示：产品销售不达预期，生产经营风险。吴斌wubin11@cmschina.com.cnS1090517040001李点典lidiandian@cmschina.com.cnS1090518100001漆经纬qijingwei@cmschina.com.cnS1090519050001重点公司主要财务指标股价18EPS19EPS20EPS19PE20PEPB评级天坛生物25.680.480.510.6150.542.27.8强烈推荐-A华兰生物30.870.811.131.2727.424.47.9强烈推荐-A资料来源：公司数据、招商证券-30-20-1001020Jul/18Nov/18Mar/19Jul/19(%)(%)医药生物沪深300行业研究敬请阅读末页的重要说明Page2正文目录一、2019H1多数血制品批签发量同比下降符合我们预期............................................4二、各主要品种分析.....................................................................................................51、人血白蛋白：国产批签发占比提升进口批签发边际改善.......................................52、静丙：19Q2批签发降幅增大..................................................................................73、凝血因子VIII...........................................................................................................84、凝血酶原复合物.......................................................................................................95、纤维蛋白原..............................................................................................................96、乙肝免疫球蛋白.....................................................................................................107、狂犬免疫球蛋白.....................................................................................................118、破伤风免疫球蛋白.................................................................................................129、肌丙.......................................................................................................................13图表目录图1：2011~2019H1国内血制品批签发概况（万瓶）................................................5图2：2011-2019H1白蛋白进口/国产批签发格局........................................................6图3：2019H1国内白蛋白份额（按批签发）..............................................................6图4：2011-2019H1静丙批签发概况...........................................................................7图5：19H1国内静丙份额（按批签发）......................................................................7图6：2011-2019H1凝血因子VIII(万瓶)批签发概况...................................................8图7：2019H1国内因子VIII份额（按批签发）..........................................................8图8：2011-2019H1凝血酶原复合物批签发（万瓶）.................................................9图9：2019H1国内PCC份额（按批签发）................................................................9图10：2011-2019H1纤维蛋白原（万瓶）批签发概况.............................................10图11：2019H1纤维蛋白原份额（按批签发）..........................................................10图12：2011-2019H1乙免(万瓶)批签发概况.............................................................11图13：2019H1国内乙免份额（按批签发）..............................................................11图14：2011-2019H1狂犬球蛋白批签发（万瓶）概况.............................................12图15：2019H1狂犬球蛋白份额（按批签发）..........................................................12图16：2011-2019H1破免(万瓶)批签发概况.............................................................13图17：2019H1破免批签发份额（按批签发）..........................................................13图18：2011-2019H1人免疫球蛋白(万瓶)批签发概况...............................................14图19：2019H1肌免份额（按批签发）.....................................................................14表1：2019H1血制品各品种批签发概况（万瓶）.......................................................5表2：2019H1进口白蛋白批签发情况（万瓶）..........................................................6表3：2019H1国产白蛋白批签发情况（万瓶）..........................................................6表4：2019H1静丙批签发情况（2.5g/瓶，万瓶)........................................................7表5：2019H1凝血因子（200IU/瓶）批签发概况.......................................................8表6：2019H1凝血酶原复合物（200IU/瓶，万瓶）批签发概况.................................9表7：2019H1人纤维蛋白原（0.5g/瓶）批签发概况................................................10表8：2019H1乙肝免疫球蛋白（200IU/瓶）批签发概况..........................................11行业研究敬请阅读末页的重要说明Page3表9：2019H1狂犬免疫球蛋白（200IU/瓶）批签发概况..........................................12表10：2019H1破免（250mg/瓶）批签发概况.........................................................13表11：2019H1人免疫球蛋白（300mg/瓶）批签发概况...........................................14行业研究敬请阅读末页的重要说明Page4一、2019H1多数血制品批签发量同比下降符合我们预期2019H1血制品批签发品种间出现分化，19Q2主要品种增速下滑明显，但白蛋白和静丙边际变化异化。2019H1白蛋白批签发1986.6万瓶，同比-7%，但是19Q2同比-3%，降幅较19Q1的-12%明显收窄，预计19H2批签发仍将继续改善。进口白蛋白批签发同比下降达32%，国产白蛋白批签发同比增长19%。批签发下降也使白蛋白从2月份开始出现供不应求，国产龙头企业如天坛生物等受益明显。静丙19H1批签发465.0万瓶，同比-7%，19Q2同比-20%。我们判断原因是，一方面，新兴事件导致静丙的批签发速度有所放慢，另一方面，静丙去年年底企业库存仍然较多，企业在年初计划可能会增加特免生产，控制静丙生产。但是，由于新兴事件导致医生患者不信任小企业，静丙需求向大企业集中，因此，龙头企业的静丙的企业库存和渠道库存在上半年都出现下降，景气向好。VIII因子19H1批签发67.9万瓶，同比-19%，19Q2同比-42%。华兰生物生产线改造影响批签发。PCC19H1批签发41.0万瓶，同比-24%，19Q2同比-23%。华兰生物生产线改造影响批签发。纤原是唯一一个批签发增长的因子类产品，19H1批签发数量43.4万瓶，同比+29%，19Q2同比+11%。泰邦生物批签发同比增长较快。19H1狂免批签发数量419.1万瓶，同比+15%，华兰、莱士、泰邦批签发量下降。天坛基本持平，双林生物今年恢复批签发之后，产量较大。19H1乙免批签发50.9万瓶，同比-27%，是三大特免中唯一下降的品种。主要供应厂家华兰、天坛、泰邦、卫光今年批签发量都非常少。19H1破免批签发242.0万瓶，同比+79%。除了华兰批签发量同比下降之外，其他主要供应厂家天坛、莱士、泰邦批签发量都大幅增长。血制品2018年批签发保持整体平稳增长。按标准瓶计算，主要产品人血白蛋白和静丙、批签发数量分别为4487.8万、1037.2万，增速分别为+9%和-7%（2016年同比增速分别为+6%和0%）。因子类产品VIII因子、PCC和纤元批签发数量分别为169.0万、98.7万和88.7万，同比增速分别为+30%、0%和-6%。特免品种中狂免、破免和乙免批签发数量分别为722.6万、350.7万和150.6万，同比分别+53%、-21%和+14%。行业研究敬请阅读末页的重要说明Page5图1：2011~2019H1国内血制品批签发概况（万瓶）资料来源：中检所、招商证券表1：2019H1血制品各品种批签发概况（万瓶）品种2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A白蛋白(10g/瓶）839.21986.61147.49%-12%-7%-3%4487.8静丙（2.5g/瓶）236.8465.0228.2-4%12%-7%-20%1037.2VIII因子（200IU/瓶）36.567.931.430%22%-19%-42%169.0PCC（200IU/瓶）15.041.026.00%-26%-24%-23%98.7纤原（0.5g/瓶）28.043.415.4-6%43%29%11%88.7狂免（200IU/瓶）162.9419.1256.253%93%15%-9%722.6乙免（200IU/瓶）6.650.944.314%-83%-27%41%150.6破免（250IU/瓶）107.7242.9135.3-21%20%79%192%321.8资料来源：中检所、招商证券二、各主要品种分析1、人血白蛋白：国产批签发占比提升进口批签发边际改善2019H1白蛋白批签发1986.6万瓶，同比-7%；2019Q2批签发1147.4万瓶，同比-3%，19Q2批签发数量边际改善明显。2019H1进口白蛋白批签发1006.8万瓶，同比-23%，占比51%；国产人血白蛋白批签量979.4万瓶，同比+19%，占比约49%，结束了2016年~2018年以来进口批签发占比58%的局面。2019Q2进口白蛋白批签发680.4万瓶，同比-5%，占比59%；国产人血白蛋白批签量468.2万瓶，同比增长1%，占比41%。19Q2进口白蛋白批签发恢复，占比回升。2019H1市场份额占比较高的是CSLBehring（杰特贝林）、Grifols（基立福）、Baxter、Octapharma等，前4公司占比49%，前8公司（国内是上市公司母公司+控股子公司）占比81%，较2018A的83%略有下降。2019H1CSLBehring、Grifols、Baxter和Octapharma批签发量分别为487.1万瓶、02000400060008000201120122013201420152016201720182019H1白蛋白（折合10g/瓶）静丙（折合2.5g）八因子（折合200IU）PCC（折合200IU）纤原（折合0.5g）狂免（折合200IU）破免（折合250IU)乙免（折合200IU）肌丙（折合150mg）行业研究敬请阅读末页的重要说明Page6159.0万瓶、220.1万瓶和115.4万瓶，同比分别-20%、-54%、+19%和-21%。天坛生物和泰邦生物在2019H1白蛋白批签发份额和同比增速方面脱颖而出。国产血制品公司前四分别是：天坛生物、华兰生物、上海莱士、泰邦生物，2019H1白蛋白批签发分别为217.1万、101.1万、104.0万和206.4万，占比分别为11%、5%、5%、10%。可以看出其中天坛生物和泰邦生物占比较另外其他国内血制品集团高出不少，且超过了排名第三的外企Grifols，份额排名第三和第四。图2：2011-2019H1白蛋白进口/国产批签发格局图3：2019H1国内白蛋白份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表2：2019H1进口白蛋白批签发情况（万瓶）品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A人血白蛋白CSLBehring196.2487.1290.93%-33%-20%-8%1031.3Grifols49.3159.0109.715%-74%-54%-29%669.2Baxter68.2220.1152.03%24%19%17%483.6Octapharma0.0115.4115.426%-100%-21%22%378.6进口合计326.31006.8680.49%-45%-23%-5%2625.0资料来源：中检所、各地方药检所、招商证券表3：2019H1国产白蛋白批签发情况（万瓶）品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A人血白蛋白天坛生物合计108.9217.1108.210%131%32%-8%369.1华兰生物合计74.7101.126.48%70%-2%-55%253.9上海莱士合计50.0110.260.2-5%43%9%-9%230.2泰邦生物合计123.7206.482.76%66%73%86%294.9博雅生物17.633.315.726%17%11%4%86.2卫光生物19.843.824.010%3%41%104%76.5双林生物15.339.624.3-18%-47%-14%45%63.9博晖创新合计2.211.39.11%-70%-37%-16%51.9上海新兴2.32.30.022%54%-49%-100%20.7丹霞生物0.00.00.0-100%---0.0远大蜀阳17.169.051.87%-59%-18%21%177.0南岳生物25.245.420.29%154%71%22%68.3哈尔滨派斯菲科12.644.031.5--337%212%24.8山西康宝26.641.815.221%-7%-5%-3%92.5新疆德源9.89.80.0205%--63%-100%26.4武汉中原瑞德3.43.40.0-21%-26%-77%-100%26.0国产总计（万瓶）509.2978.5469.38%43%19%1%1862.342%42%49%0%20%40%60%80%100%进口国内进口企业51%天坛生物11%华兰生物5%上海莱士5%泰邦生物10%博雅生物2%其他16%行业研究敬请阅读末页的重要说明Page7资料来源：中检所、各地方药检所、招商证券2、静丙：19Q2批签发降幅增大2014-2016年国内静丙批签发都保持了20%以上的增速。2017、2018年连续两年，静丙批签发同比持平或者略有微降。2019H1共批签发静丙465.0万瓶，同比-7%。19Q2静丙批签发受新兴事件影响明显，合计批签发151.7万瓶，同比-47%。2019H1主要厂家有（50万批签发以上）：天坛系（118.2万，同比-1%）、泰邦系（101.7万，同比+11%）、莱士系（26.8万，同比-52%）、华兰系（48.4万，同比-12%）、远大蜀阳（41.3万，同比-21.7%）。博雅生物19H1批签发25.1万瓶，同比-2%。图4：2011-2019H1静丙批签发概况图5：19H1国内静丙份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表4：2019H1静丙批签发情况（2.5g/瓶，万瓶)品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A静丙天坛生物合计47.2118.271.117%47%-1%-18%281.6华兰生物合计35.748.412.7-31%98%-12%-66%106.5上海莱士合计10.729.218.6-16%-55%-48%-44%127.7泰邦生物合计61.5101.740.2-1%22%11%-2%164.9博雅生物10.425.114.740%-17%-2%14%67.9卫光生物2.316.314.0-19%-78%-27%16%36.0双林生物3.87.73.8-26%-64%-47%2%23.6博晖创新合计0.00.90.9-32%-100%-75%-8%5.2上海新兴0.00.00.041%-100%-100%-100%14.3远大蜀阳19.641.321.7-23%-17%-22%-25%81.8南岳生物13.723.09.3-8%199%164%125%30.7哈尔滨派斯菲科13.821.07.3--1102%317%4.9山西康宝12.524.612.12%-15%-10%-4%61.0武汉中原瑞德3.53.50.046%-23%-72%-100%25.0绿十字1.74.62.9-39%91%72%62%6.0总计236.3465.5229.3-4%12%-6%-20%1037.3-20%-10%0%10%20%30%40%020040060080010001200静丙批签发，万瓶（折合2.5g）同比增长天坛生物26%华兰生物10%上海莱士6%泰邦生物22%博雅生物5%其他31%行业研究敬请阅读末页的重要说明Page8资料来源：中检所、招商证券3、凝血因子VIII由于血友病病人需终身使用凝血因子，国内患病人群大，凝血因子供给少，是血制品中供需缺口最大的品种，尽管由于国家进口重组凝血因子，但由于价格昂贵一般患者承受不起。2010-2018年凝血因子VIII批签发迅速上升，CAGR为24%。2018年批签量为169.0万瓶，同比+30%。2018年国内共有5家企业获得凝血因子VIII批签发：华兰生物、山东泰邦、绿十字、上海莱士、和上海新兴。2019H1，凝血因子VIII（按200IU/瓶折算）批签发67.9万瓶，同比增长-19%，出现了罕见的下滑，我们估计主要是华兰生物生产线改造造成；19Q2批签发31.3万瓶，同比-42%，主要是19Q2同比下滑较多。2019H1，华兰生物、绿十字、山东泰邦、上海莱士、上海新兴，批签发分为28.2万（同比-31%）、9.5万（同比-47%）、23.4万（同比+58%）、6.8万（同比-27%）、0万瓶（同比-100%）。其中华兰生物占比42%，继续保持主导地位，但此消彼长后泰邦生物占比也达到了35%。图6：2011-2019H1凝血因子VIII(万瓶)批签发概况图7：2019H1国内因子VIII份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表5：2019H1凝血因子（200IU/瓶，万瓶）批签发概况品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A凝血因子华兰生物24.028.24.126%73%-31%-85%64.6泰邦生物6.323.417.2104%20%58%78%34.9绿十字3.29.56.344%29%-47%-59%42.2上海莱士3.06.83.8-21%-64%-28%263%24.2上海新兴0.00.00.068%--100%-100%3.1总计36.567.931.430%22%-19%-42%169.0资料来源：中检所、招商证券-40%-20%0%20%40%60%80%050100150200八因子（折合200IU）同比增长绿十字14%上海新兴0%上海莱士10%华兰生物41%泰邦生物35%行业研究敬请阅读末页的重要说明Page94、凝血酶原复合物凝血酶原复合物（PCC）主要用于预防和治疗因凝血因子Ⅱ、Ⅶ、Ⅸ及Ⅹ缺乏导致的出血，如乙型血友病、严重肝病及弥散性血管内凝血（DIC）。国内有进口的辉瑞重组人Ⅸ因子产品，但价格昂贵（2135元/250IU），因此凝血酶原复合物为乙型血友病（Ⅸ因子缺陷）的救命药。凝血酶原复合物生产工艺较为复杂，在生产过程中Ⅸ因子容易降解失去活性,达不到新版药典规定的效价指标，不能通过批签发，导致成本较高。近年来凝血酶原复合物的价格有所提升，企业生产的积极性有所加强。2010年至2018年凝血酶原复合物批签量快速增长，CAGR为23%。2018年批签量为98.7万瓶，同比上升-0.3%。2018年华兰生物占比46%，占据主导地位。2019H1，凝血酶原复合物共批签发（按200IU/瓶折算）41.0万瓶，同比-24%。其中，华兰生物批签发15.7万瓶，同比增-44%；泰邦生物批签发23.8万瓶，同比-46%。图8：2011-2019H1凝血酶原复合物批签发（万瓶）图9：2019H1国内PCC份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表6：2019H1凝血酶原复合物（200IU/瓶，万瓶）批签发概况品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A凝血酶原复合物泰邦生物13.523.810.246%93%12%-28%38.0华兰生物0.015.715.7-30%-100%-44%4%45.6上海新兴1.51.50.0102%200%-70%-100%15.1合计15.041.026.00%-26%-24%-23%98.7资料来源：中检所、招商证券5、纤维蛋白原人纤维蛋白原在经过了2013年GMP改造影响后保持了高增长的态势，经历了15年底开始的大幅提价后，2016年企业大幅扩产，渠道库存增加，导致2017年开始批签发-40%-20%0%20%40%60%020406080100120PCC（折合200IU）同比增长上海新兴4%华兰生物38%泰邦生物58%行业研究敬请阅读末页的重要说明Page10放缓。2018年批签发为88.7万瓶（按0.5g/瓶折算），同比-6%。2019H1，纤维蛋白原批签发43.4万瓶（按0.5g/瓶折算），同比+30%，主要是泰邦生物批签发增加较多导致：上海莱士纤原批签发15.0万瓶，同比+230%。博雅生物纤原批签发19.6，同比持平。纤原竞争格局由一强主导变为两强相争。2018年纤原批签发份额中，博雅生物占比高达57%，第二名上海莱士占比14%。但随着2019H1三季度泰邦生物纤原批签发的大幅提升，其占比上升到13.92%，占比上升到34%。图10：2011-2019H1纤维蛋白原（万瓶）批签发概况图11：2019H1纤维蛋白原份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表7：2019H1人纤维蛋白原（0.5g/瓶，万瓶）批签发概况品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A人纤维蛋白原博雅生物12.119.67.594%2%0%96%50.7泰邦生物9.515.05.4-489%230%186%11.6上海新兴2.82.80.024%20%5%0%6.4绿十字1.02.81.8-100%---0.0上海莱士2.32.30.0-74%41%-8%0%12.7哈尔滨派斯菲科0.00.70.7----0.0华兰生物0.20.20.01%-88%-94%0%7.128.043.415.4-6%43%29%111%88.7资料来源：中检所，招商证券6、乙肝免疫球蛋白2011年-2014国内年乙肝球蛋白生产量连续下降，2014-2018年乙免批签发没有显著变化。2018年签发132万瓶，同比下降-7%。2019H1，乙肝免疫球蛋白（折算成200IU/瓶）批签发50.9万瓶，同比增长-27%。主要的批签发企业有上海莱士和天坛生物。2019H1，共有5家企业批签发乙肝免球蛋白，较2017年的8家较少了2家，市场集中度进一步提高。占比较大的天坛生物和上海莱士分别批签发13.8万瓶和19.9万瓶，分别同比-13%和+210%。份额下降较多的有华兰生物和远大蜀阳，分别批签发6.6万-50%0%50%100%150%200%020406080100120纤原（折合0.5g）同比增长博雅生物45%上海莱士5%泰邦生物34%华兰生物1%绿十字6%哈尔滨派斯菲科2%行业研究敬请阅读末页的重要说明Page11瓶和5.9万瓶，分别同比-58%和67%。图12：2011-2019H1乙免(万瓶)批签发概况图13：2019H1国内乙免份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表8：2019H1乙肝免疫球蛋白（200IU/瓶，万瓶）批签发概况品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A乙肝免疫球蛋白上海莱士0.019.919.921.2-100%211%-21.2天坛生物0.013.813.815.9-100%-13%307%15.9华兰生物6.66.60.030.0-19%-58%0%30.0远大蜀阳0.05.95.929.2-100%-67%44%29.2泰邦生物0.04.64.621.7-80%180%21.7南岳生物0.00.00.014.0-100%-100%-14.0博雅生物0.00.00.00.0---0.0卫光生物0.00.00.018.6--100%0%18.6总计6.650.944.3150.6-83%-27%141%150.6资料来源：中检所，招商证券7、狂犬免疫球蛋白2008年-2014年国内狂犬球蛋白(折算成200IU/瓶)批签量快速增长，CAGR24%，2014年批签量达631.81万瓶。随着国内加强宠物、流浪猫狗管理，再加上狂犬疫苗的冲击，狂犬球蛋白需求出现下滑，批签量回调。2015-2016年批签量大幅下滑。2017年开始狂免批签发开始回升：2018年批签发722.6万瓶，同比增长53%；2019H1批签发419.1万瓶，同比增长15%。卫光和双林市场份额重回前列。2017年狂免批签发份额前三厂家分别为双林生物（ST生化旗下，占比25%）、泰邦生物（20%）、卫光生物（12%），合计占比57.63%。2018年卫光和双林市场份额分别只有4%和2%。2019H1卫光和双林分别批签发55.2万瓶和68.7万瓶；卫光批签发同比+530%，双林2018H1无批签发；卫光和双林2019H1的份额分别回到了13%和16%。2018年批签发前四厂家华兰生物、上海莱士、泰邦生物、远大蜀阳2019H1批签发分别同比-46%、-26%、-12%、-7%。-40%-30%-20%-10%0%10%20%050100150200250300乙免（折合200IU）同比增长上海莱士39%南岳生物0%博雅生物0%卫光生物0%天坛生物27%华兰生物13%远大蜀阳12%泰邦生物9%行业研究敬请阅读末页的重要说明Page12图14：2011-2019H1狂犬球蛋白批签发（万瓶）概况图15：2019H1狂犬球蛋白份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表9：2019H1狂犬免疫球蛋白（200IU/瓶，万瓶）批签发概况品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A狂犬免疫球蛋白双林生物35.568.733.2-86%---16.1上海莱士22.162.740.5180%-7%-26%67%140.5泰邦生物19.457.838.427%-26%-12%97%121.7卫光生物9.455.245.9-53%-530%523%27.4远大蜀阳20.646.225.680%116%-7%64%79.7天坛生物12.739.526.8--3%70%64.7华兰生物28.736.27.4219%58%-46%15%150.0南岳生物14.527.413.011%--15%40%48.3博雅生物0.025.425.4200%-100%35%207%45.3上海新兴0.00.00.0----2.6博晖创新0.00.00.0----26.3总计84.38364.95518.0796%63%16%472.02资料来源：中检所，招商证券8、破伤风免疫球蛋白2008-2014年，破免批签发处于小幅波动状态，平均每年批签发193万瓶。2014-2017年破免批签发逐年上升，但2017年批签发增速已经放缓。2018年批签发同比下降21%。2019H1批签发237.7万瓶，同比+75%，增速有所回升。天坛生物份额大幅提升，华兰生物份额大幅下降：2019H1天坛生物和华兰生物分别批签发70.2万瓶和23.6万瓶，分别同比+96%和-55%，份额占比分别为29%和10%。泰邦生物批签发58.8万瓶，同比+223%，份额占比位居第二。-60%-40%-20%0%20%40%60%80%0200400600800狂免（折合200IU）同比增长双林生物16%上海莱士15%泰邦生物14%卫光生物13%远大蜀阳11%天坛生物9%华兰生物9%南岳生物7%博雅生物6%行业研究敬请阅读末页的重要说明Page13图16：2011-2019H1破免(万瓶)批签发概况图17：2019H1破免批签发份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表10：2019H1破免（250mg/瓶，万瓶）批签发概况品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A破免天坛生物21.870.348.5-26%-39%96%-49.8泰邦生物23.558.935.3-36%258%223%304%63.8远大蜀阳18.737.518.848%---38.6上海莱士14.628.514.065%5%107%#DIV/0!40.6华兰生物23.623.60.0-29%3%-55%0%92.1卫光生物5.510.55.0-80%-97%94%5.4双林生物0.08.48.4-69%---20.7GC绿十字0.00.00.0----0.0南岳生物0.00.00.0--100%-100%-10.6卫光生物0.005.355.35---43%-100%27.3武汉瑞德0.000.000.00-100%-100%-100%-1.62合计107.7242.9135.3-27%20%79%292%321.8资料来源：中检所，招商证券9、肌丙2010年开始肌注人免疫球蛋白批签发量呈3年一个周期波动，平均每年批签发210万瓶左右。2010-2012年上升，2012年爆发，批签发超过400万瓶（折算成300IU/瓶）。2012-2014年下降，2014年批签发量小于100万瓶。2014-2016年开始上升，2016年批签发312.20万瓶。2016-2018Q1-3处在下降周期，估计18年批签发量不超过100万瓶。2019H1批签发并没有上升，我们估计是在静丙的冲击下肌丙需求下滑造成。2019H1，肌丙批签发43.2万瓶，同比-32%；2018A有5家批签发，2019H1只有3家有批签发，其中上海莱士占比66%。其中华兰系5.9万瓶（同比-90%），上海莱士28.7万瓶（18A没有批签发），泰邦生物8.6万瓶（18A没有批签发）。-40%-20%0%20%40%60%80%100%0100200300400500破免（折合250IU)同比增长天坛生物30%泰邦生物25%远大蜀阳16%上海莱士12%华兰生物10%卫光生物4%双林生物3%行业研究敬请阅读末页的重要说明Page14图18：2011-2019H1人免疫球蛋白(万瓶)批签发概况图19：2019H1肌免份额（按批签发）资料来源：中检所，招商证券资料来源：中检所，招商证券表11：2019H1人免疫球蛋白（300mg/瓶，万瓶）批签发概况品种厂商2019Q12019H12019Q22018A同比2019Q1同比2019H1同比2019Q2同比2018A肌丙上海莱士28.728.70.0-100%---0.0泰邦生物8.68.60.0-100%---0.0华兰生物5.95.90.0218%49%-90%0%69.2丹霞生物0.00.00.0----0.0卫光生物0.00.00.0-32%---24.9双林生物0.00.00.0--100%-100%-6.0河北大安0.00.00.0-68%---33.2远大蜀阳0.00.00.0156%---16.1总计43.243.20.0-26%332%-32%0%149.4资料来源：中检所，招商证券-100%-50%0%50%100%150%200%250%300%0100200300400500肌丙（折合150mg）同比增长华兰生物14%上海莱士66%泰邦生物20%行业研究敬请阅读末页的重要说明Page15分析师承诺负责本研究报告的每一位证券分析师，在此申明，本报告清晰、准确地反映了分析师本人的研究观点。本人薪酬的任何部分过去不曾与、现在不与，未来也将不会与本报告中的具体推荐或观点直接或间接相关。吴斌，中科院大学管理科学与工程硕士，武汉大学生物技术学士，8年证券从业经验，2017年加入招商证券，任医药行业首席分析师。李勇剑，北京大学医学部药物化学系硕士，1年医药行业经验，2013年7月加入招商证券，任医药行业分析师。李点典，香港科技大学生化系硕士，2016年加入招商证券，任医药行业分析师。漆经纬，美国乔治华盛顿大学硕士，1年美国私募对冲基金研究经验，1年国内证券从业经验，2018年3月加入招商证券，任医药行业分析师。投资评级定义公司短期评级以报告日起6个月内，公司股价相对同期市场基准（沪深300指数）的表现为标准：强烈推荐：公司股价涨幅超基准指数20%以上审慎推荐：公司股价涨幅超基准指数5-20%之间中性：公司股价变动幅度相对基准指数介于±5%之间回避：公司股价表现弱于基准指数5%以上公司长期评级A：公司长期竞争力高于行业平均水平B：公司长期竞争力与行业平均水平一致C：公司长期竞争力低于行业平均水平行业投资评级以报告日起6个月内，行业指数相对于同期市场基准（沪深300指数）的表现为标准：推荐：行业基本面向好，行业指数将跑赢基准指数中性：行业基本面稳定，行业指数跟随基准指数回避：行业基本面向淡，行业指数将跑输基准指数重要声明本报告由招商证券股份有限公司（以下简称“本公司”）编制。本公司具有中国证监会许可的证券投资咨询业务资格。本报告基于合法取得的信息，但本公司对这些信息的准确性和完整性不作任何保证。本报告所包含的分析基于各种假设，不同假设可能导致分析结果出现重大不同。报告中的内容和意见仅供参考，并不构成对所述证券买卖的出价，在任何情况下，本报告中的信息或所表述的意见并不构成对任何人的投资建议。除法律或规则规定必须承担的责任外，本公司及其雇员不对使用本报告及其内容所引发的任何直接或间接损失负任何责任。本公司或关联机构可能会持有报告中所提到的公司所发行的证券头寸并进行交易，还可能为这些公司提供或争取提供投资银行业务服务。客户应当考虑到本公司可能存在可能影响本报告客观性的利益冲突。本报告版权归本公司所有。本公司保留所有权利。未经本公司事先书面许可，任何机构和个人均不得以任何形式翻版、复制、引用或转载，否则，本公司将保留随时追究其法律责任的权利。","data":[{"id":"1","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2019H1白蛋白批签发1986.6万瓶","content_offset":["542","562"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1986.6万瓶","554","562"],"indicator_element":{"时间":["2019H1","542","548"],"产品":["白蛋白","548","551"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-7%","content_offset":["563","568"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-7%","565","568"],"indicator_element":{"时间":["2019H1","513","519"],"产品":["白蛋白","519","522"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19Q2批签发同比仅下降3%","content_offset":["667","681"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降3%","677","681"],"indicator_element":{"时间":["19Q2","667","671"],"产品":["白蛋白","575","578"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"静丙19H1批签发465.0万瓶","content_offset":["822","838"],"indicators":[{"indicator_name":"批签发量","indicator_value":["465.0万瓶","831","838"],"indicator_element":{"时间":["19H1","824","828"],"产品":["静丙","822","824"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-7%","content_offset":["563","568"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-7%","565","568"],"indicator_element":{"时间":["19H1","515","519"],"产品":["静丙","793","795"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19Q2同比-20%","content_offset":["845","855"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-20%","851","855"],"indicator_element":{"时间":["19Q2","845","849"],"产品":["静丙","793","795"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"VIII因子19H1批签发67.9万瓶","content_offset":["1013","1032"],"indicators":[{"indicator_name":"批签发量","indicator_value":["67.9万瓶","1026","1032"],"indicator_element":{"时间":["19H1","1019","1023"],"产品":["VIII因子","1013","1019"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-19%","content_offset":["1033","1039"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-19%","1035","1039"],"indicator_element":{"时间":["19H1","1019","1023"],"产品":["VIII因子","1013","1019"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19Q2同比-42%","content_offset":["1040","1050"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-42%","1046","1050"],"indicator_element":{"时间":["19Q2","1040","1044"],"产品":["VIII因子","1013","1019"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"PCC19H1批签发41.0万瓶","content_offset":["1051","1067"],"indicators":[{"indicator_name":"批签发量","indicator_value":["41.0万瓶","1061","1067"],"indicator_element":{"时间":["19H1","1054","1058"],"产品":["PCC","1051","1054"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-24%","content_offset":["1068","1074"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-24%","1070","1074"],"indicator_element":{"时间":["19H1","1019","1023"],"产品":["PCC","1051","1054"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19Q2同比-23%","content_offset":["1075","1085"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-23%","1081","1085"],"indicator_element":{"时间":["19Q2","1075","1079"],"产品":["PCC","1051","1054"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"纤原19H1批签发数量43.4万瓶","content_offset":["1157","1174"],"indicators":[{"indicator_name":"批签发量","indicator_value":["43.4万瓶","1168","1174"],"indicator_element":{"时间":["19H1","1159","1163"],"产品":["纤原","1157","1159"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比+29%","content_offset":["1175","1181"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+29%","1177","1181"],"indicator_element":{"时间":["19H1","1159","1163"],"产品":["纤原","1157","1159"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"进口白蛋白批签发同比下降达32%","content_offset":["5359","5375"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降达32%","5369","5375"],"indicator_element":{"时间":["2019H1","5287","5293"],"产品":["白蛋白","5361","5364"],"渠道":["进口","5359","5361"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"国产白蛋白批签发同比增长19%","content_offset":["5376","5391"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长19%","5386","5391"],"indicator_element":{"时间":["2019H1","5287","5293"],"产品":["白蛋白","5378","5381"],"渠道":["国产","5376","5378"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19Q2同比+11%","content_offset":["5754","5764"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+11%","5760","5764"],"indicator_element":{"时间":["19Q2","5754","5758"],"产品":["纤原","5712","5714"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19H1狂免批签发数量419.1万瓶","content_offset":["5779","5797"],"indicators":[{"indicator_name":"批签发量","indicator_value":["419.1万瓶","5790","5797"],"indicator_element":{"时间":["19H1","5779","5783"],"产品":["狂免","5783","5785"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比+15%","content_offset":["5798","5804"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+15%","5800","5804"],"indicator_element":{"时间":["19H1","5731","5735"],"产品":["狂免","5783","5785"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19H1乙免批签发50.9万瓶","content_offset":["5846","5861"],"indicators":[{"indicator_name":"批签发量","indicator_value":["50.9万瓶","5855","5861"],"indicator_element":{"时间":["19H1","5846","5850"],"产品":["乙免","5850","5852"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-27%","content_offset":["5862","5868"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-27%","5864","5868"],"indicator_element":{"时间":["19H1","5779","5783"],"产品":["乙免","5850","5852"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19H1破免批签发242.0万瓶","content_offset":["5911","5927"],"indicators":[{"indicator_name":"批签发量","indicator_value":["242.0万瓶","5920","5927"],"indicator_element":{"时间":["19H1","5911","5915"],"产品":["破免","5915","5917"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比+79%","content_offset":["5928","5934"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+79%","5930","5934"],"indicator_element":{"时间":["19H1","5846","5850"],"产品":["破免","5915","5917"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"主要产品人血白蛋白和静丙、批签发数量分别为4487.8万、1037.2万","content_offset":["6003","6039"],"indicators":[{"indicator_name":"批签发量","indicator_value":["4487.8万","6024","6031"],"indicator_element":{"产品":["人血白蛋白","6007","6012"],"时间":["2018年","5979","5984"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["1037.2万","6032","6039"],"indicator_element":{"产品":["静丙","6013","6015"],"时间":["2018年","5979","5984"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"增速分别为+9%和-7%","content_offset":["6040","6052"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+9","6045","6047"],"indicator_element":{"产品":["人血白蛋白","6007","6012"],"时间":["2018年","5979","5984"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-7%","6049","6052"],"indicator_element":{"产品":["静丙","6013","6015"],"时间":["2018年","5979","5984"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2016年同比增速分别为+6%和0%","content_offset":["6053","6071"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+6","6065","6067"],"indicator_element":{"产品":["人血白蛋白","6007","6012"],"时间":["2016年","6053","6058"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["0%","6069","6071"],"indicator_element":{"产品":["静丙","6013","6015"],"时间":["2016年","6053","6058"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"因子类产品VIII因子、PCC和纤元批签发数量分别为169.0万、98.7万和88.7万","content_offset":["6073","6117"],"indicators":[{"indicator_name":"批签发量","indicator_value":["169.0万","6099","6105"],"indicator_element":{"产品":["VIII因子","6078","6084"],"时间":["2018年","5979","5984"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["98.7万","6106","6111"],"indicator_element":{"产品":["PCC","6085","6088"],"时间":["2018年","5979","5984"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["88.7万","6112","6117"],"indicator_element":{"产品":["纤元","6089","6091"],"时间":["2018年","5979","5984"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比增速分别为+30%、0%和-6%","content_offset":["6118","6136"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+30%","6125","6129"],"indicator_element":{"产品":["VIII因子","6078","6084"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["0%","6127","6129"],"indicator_element":{"产品":["PCC","6085","6088"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-6%","6133","6136"],"indicator_element":{"产品":["纤元","6089","6091"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"特免品种中狂免、破免和乙免批签发数量分别为722.6万、350.7万和150.6万","content_offset":["6137","6178"],"indicators":[{"indicator_name":"批签发量","indicator_value":["722.6万","6158","6164"],"indicator_element":{"产品":["狂免","6142","6144"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["350.7万","6165","6171"],"indicator_element":{"产品":["破免","6145","6147"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["150.6万","6172","6178"],"indicator_element":{"产品":["乙免","6148","6150"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比分别+53%、-21%和+14%","content_offset":["6179","6197"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+53%","6183","6187"],"indicator_element":{"产品":["狂免","6142","6144"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-21%","6188","6192"],"indicator_element":{"产品":["破免","6145","6147"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+14%","6193","6197"],"indicator_element":{"产品":["乙免","6148","6150"],"时间":["2018年","6875","6880"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"占比51%","content_offset":["6828","6833"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["51%","6830","6833"],"indicator_element":{"时间":["2019H1","6731","6737"],"产品":["白蛋白","6737","6740"],"渠道":["进口","6804","6806"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"占比59%","content_offset":["6924","6929"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["59%","6926","6929"],"indicator_element":{"时间":["2019H1","6981","6987"],"产品":["白蛋白","6838","6841"],"渠道":["国产","6834","6836"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2019Q2进口白蛋白批签发680.4万瓶","content_offset":["6896","6917"],"indicators":[{"indicator_name":"批签发量","indicator_value":["680.4万瓶","6910","6917"],"indicator_element":{"时间":["2019Q2","6896","6902"],"产品":["白蛋白","6904","6907"],"渠道":["进口","6902","6904"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-5%","content_offset":["6918","6923"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-5%","6920","6923"],"indicator_element":{"时间":["2019Q2","6896","6902"],"产品":["白蛋白","6838","6841"],"渠道":["进口","6882","6884"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"占比59%","content_offset":["6924","6929"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["59%","6926","6929"],"indicator_element":{"时间":["2019Q2","6896","6902"],"产品":["白蛋白","6838","6841"],"渠道":["进口","6882","6884"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"国产人血白蛋白批签量468.2万瓶","content_offset":["6930","6947"],"indicators":[{"indicator_name":"批签发量","indicator_value":["468.2万瓶","6940","6947"],"indicator_element":{"时间":["2019Q2","6896","6902"],"产品":["人血白蛋白","6932","6937"],"渠道":["国产","6930","6932"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比增长1%","content_offset":["6948","6954"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长1%","6950","6954"],"indicator_element":{"时间":["2019Q2","6896","6902"],"产品":["人血白蛋白","6932","6937"],"渠道":["国产","6930","6932"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"占比41%","content_offset":["6955","6960"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["41%","6957","6960"],"indicator_element":{"时间":["2019Q2","6896","6902"],"产品":["人血白蛋白","6932","6937"],"渠道":["国产","6930","6932"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2014-2016年国内静丙批签发都保持了20%以上的增速","content_offset":["8745","8774"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["20%","8766","8769"],"indicator_element":{"时间":["2014-2016年","8745","8755"],"区域":["国内","8755","8757"],"产品":["静丙","8757","8759"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19Q2静丙批签发受新兴事件影响明显，合计批签发151.7万瓶","content_offset":["8832","8863"],"indicators":[{"indicator_name":"批签发量","indicator_value":["151.7万瓶","8856","8863"],"indicator_element":{"时间":["19Q2","8832","8836"],"产品":["静丙","8836","8838"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-47%","content_offset":["8864","8870"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-47%","8866","8870"],"indicator_element":{"时间":["19Q2","8832","8836"],"产品":["静丙","8790","8792"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2018年批签量为169.0万瓶","content_offset":["9973","9989"],"indicators":[{"indicator_name":"批签发量","indicator_value":["169.0万瓶","9982","9989"],"indicator_element":{"时间":["2018年","9973","9978"],"产品":["凝血因子VIII","9948","9956"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比+30%","content_offset":["9990","9996"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+30%","9992","9996"],"indicator_element":{"时间":["2018年","9943","9948"],"产品":["凝血因子VIII","9948","9956"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"19Q2批签发31.3万瓶","content_offset":["10123","10136"],"indicators":[{"indicator_name":"批签发量","indicator_value":["31.3万瓶","10130","10136"],"indicator_element":{"时间":["19Q2","10123","10127"],"产品":["凝血因子VIII","10056","10064"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-42%","content_offset":["1044","1050"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-42%","1046","1050"],"indicator_element":{"时间":["19Q2","1040","1044"],"产品":["凝血因子VIII","1898","1906"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2018年批签量为98.7万瓶","content_offset":["11052","11067"],"indicators":[{"indicator_name":"批签发量","indicator_value":["98.7万瓶","11061","11067"],"indicator_element":{"时间":["2018年","11052","11057"],"产品":["凝血酶原复合物","10989","10996"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比上升-0.3%","content_offset":["11068","11077"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["上升-0.3%","11070","11077"],"indicator_element":{"时间":["2018年","11023","11028"],"产品":["凝血酶原复合物","10989","10996"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2019H1，凝血酶原复合物共批签发（按200IU/瓶折算）41.0万瓶","content_offset":["11100","11136"],"indicators":[{"indicator_name":"批签发量","indicator_value":["41.0万瓶","11130","11136"],"indicator_element":{"时间":["2019H1","11100","11106"],"产品":["凝血酶原复合物","11107","11114"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-24%","content_offset":["1068","1074"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-24%","1070","1074"],"indicator_element":{"时间":["2019H1","1550","1556"],"产品":["凝血酶原复合物","2016","2023"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2018年批签发为88.7万瓶（按0.5g/瓶折算）","content_offset":["11691","11717"],"indicators":[{"indicator_name":"批签发量","indicator_value":["88.7万瓶","11700","11706"],"indicator_element":{"时间":["2018年","11691","11696"],"产品":["人纤维蛋白原","12017","12023"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-6%","content_offset":["11718","11723"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-6%","11720","11723"],"indicator_element":{"时间":["2018年","11691","11696"],"产品":["人纤维蛋白原","12017","12023"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2019H1，纤维蛋白原批签发43.4万瓶","content_offset":["11724","11745"],"indicators":[{"indicator_name":"批签发量","indicator_value":["43.4万瓶","11739","11745"],"indicator_element":{"时间":["2019H1","11724","11730"],"产品":["纤维蛋白原","11731","11736"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比+30%","content_offset":["9990","9996"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+30%","9992","9996"],"indicator_element":{"时间":["2019H1","10049","10055"],"产品":["纤维蛋白原","11512","11517"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2018年签发132万瓶","content_offset":["12391","12403"],"indicators":[{"indicator_name":"批签发量","indicator_value":["132万瓶","12398","12403"],"indicator_element":{"时间":["2018年","12391","12396"],"产品":["乙肝球蛋白","12356","12361"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比下降-7%","content_offset":["12404","12411"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降-7%","12406","12411"],"indicator_element":{"时间":["2018年","12374","12379"],"产品":["乙肝球蛋白","12356","12361"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2019H1，乙肝免疫球蛋白（折算成200IU/瓶）批签发50.9万瓶","content_offset":["12412","12447"],"indicators":[{"indicator_name":"批签发量","indicator_value":["50.9万瓶","12441","12447"],"indicator_element":{"时间":["2019H1","12412","12418"],"产品":["乙肝球蛋白","12356","12361"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比增长-27%","content_offset":["12448","12456"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长-27%","12450","12456"],"indicator_element":{"时间":["2019H1","12412","12418"],"产品":["乙肝球蛋白","12356","12361"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2014年批签量达631.81万瓶","content_offset":["13252","13269"],"indicators":[{"indicator_name":"批签发量","indicator_value":["631.81万瓶","13261","13269"],"indicator_element":{"时间":["2014年","13252","13257"],"产品":["狂犬球蛋白","13219","13224"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2018年批签发722.6万瓶","content_offset":["13350","13365"],"indicators":[{"indicator_name":"批签发量","indicator_value":["722.6万瓶","13358","13365"],"indicator_element":{"时间":["2018年","13350","13355"],"产品":["狂犬球蛋白","13297","13302"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比增长53%","content_offset":["13366","13373"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长53%","13368","13373"],"indicator_element":{"时间":["2018年","13350","13355"],"产品":["狂犬球蛋白","13297","13302"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2019H1批签发419.1万瓶","content_offset":["13374","13390"],"indicators":[{"indicator_name":"批签发量","indicator_value":["419.1万瓶","13383","13390"],"indicator_element":{"时间":["2019H1","13374","13380"],"产品":["狂犬球蛋白","13297","13302"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比增长15%","content_offset":["13391","13398"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长15%","13393","13398"],"indicator_element":{"时间":["2019H1","13374","13380"],"产品":["狂犬球蛋白","13297","13302"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2008-2014年，破免批签发处于小幅波动状态，平均每年批签发193万瓶","content_offset":["14345","14382"],"indicators":[{"indicator_name":"批签发量","indicator_value":["193万瓶","14377","14382"],"indicator_element":{"时间":["2008-2014年","14345","14355"],"产品":["破免","14356","14358"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2018年批签发同比下降21%","content_offset":["14419","14434"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降21%","14429","14434"],"indicator_element":{"时间":["2018年","14419","14424"],"产品":["破免","14356","14358"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2019H1批签发237.7万瓶","content_offset":["14435","14451"],"indicators":[{"indicator_name":"批签发量","indicator_value":["237.7万瓶","14444","14451"],"indicator_element":{"时间":["2019H1","14435","14441"],"产品":["破免","14356","14358"]},"indicator_supplement":{"属性":""}}]},{"id":"65","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比+75%","content_offset":["14452","14458"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+75%","14454","14458"],"indicator_element":{"时间":["2019H1","14435","14441"],"产品":["破免","14356","14358"]},"indicator_supplement":{"属性":""}}]},{"id":"66","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2010年开始肌注人免疫球蛋白批签发量呈3年一个周期波动，平均每年批签发210万瓶左右","content_offset":["15263","15306"],"indicators":[{"indicator_name":"批签发量","indicator_value":["210万瓶","15299","15304"],"indicator_element":{"时间":["2010年","15263","15268"],"产品":["肌注人免疫球蛋白","15270","15278"]},"indicator_supplement":{"属性":""}}]},{"id":"67","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2010-2012年上升，2012年爆发，批签发超过400万瓶","content_offset":["15307","15338"],"indicators":[{"indicator_name":"批签发量","indicator_value":["超过400万瓶","15331","15338"],"indicator_element":{"时间":["2010-2012年","15307","15317"],"产品":["肌注人免疫球蛋白","15270","15278"]},"indicator_supplement":{"属性":""}}]},{"id":"68","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2014年批签发量小于100万瓶","content_offset":["15364","15380"],"indicators":[{"indicator_name":"批签发量","indicator_value":["小于100万瓶","15373","15380"],"indicator_element":{"时间":["2014年","15364","15369"],"产品":["肌注人免疫球蛋白","15270","15278"]},"indicator_supplement":{"属性":""}}]},{"id":"69","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2016年批签发312.20万瓶","content_offset":["15396","15412"],"indicators":[{"indicator_name":"批签发量","indicator_value":["312.20万瓶","15404","15412"],"indicator_element":{"时间":["2016年","15396","15401"],"产品":["肌注人免疫球蛋白","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"70","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"估计18年批签发量不超过100万瓶","content_offset":["15433","15450"],"indicators":[{"indicator_name":"批签发量","indicator_value":["不超过100万瓶","15442","15450"],"indicator_element":{"时间":["18年","15435","15438"],"产品":["肌注人免疫球蛋白","-1","-1"]},"indicator_supplement":{"属性":"估计"}}]},{"id":"71","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"2019H1，肌丙批签发43.2万瓶","content_offset":["15487","15505"],"indicators":[{"indicator_name":"批签发量","indicator_value":["43.2万瓶","15499","15505"],"indicator_element":{"时间":["2019H1","15487","15493"],"产品":["肌丙","15494","15496"]},"indicator_supplement":{"属性":""}}]},{"id":"72","source_document":"血制品行业2019上半年批签发报告：批签发向国产龙头集中，强者恒强.pdf","content":"同比-32%","content_offset":["15506","15512"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-32%","15508","15512"],"indicator_element":{"时间":["2019H1","15451","15457"],"产品":["肌丙","15478","15480"]},"indicator_supplement":{"属性":""}}]}]}